BioStock: Curasight targets clinical proof-of-concept for uTREAT

Having secured financing for the ongoing clinical development of uTRACE, Curasight can now enter the next level in developing the therapeutic side of its theranostic approach. This will be done by rapidly achieving proof-of-concept in a single indication with uTREAT. BioStock contacted CEO Ulrich Krasilnikoff in conjunction with the Q2 report to learn more.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/08/curasight-targets-clinical-proof-of-concept-for-utreat/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se